Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
Abstract
:1. Introduction
2. Lipid Metabolism in Ovarian Cancer
Fatty Acid Synthase (FAS)
3. Lipids
3.1. Phospholipids
3.1.1. Autotaxin (ATX)
3.1.2. Phospholipase A
3.1.3. Phospholipase D (PLD)
3.2. Sphingolipids
3.3. Glycosphingolipids
4. Lipids as Diagnostic Markers and Therapeutic Targets in Ovarian Cancer
4.1. Diagnostic Markers
4.2. Therapeutic Targets
5. Conclusions
Acknowledgements
Conflict of Interest
References
- Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63, 11–30. [Google Scholar]
- Agarwal, R.; Kaye, S.B. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502–516. [Google Scholar]
- Xiao, Y.; Chen, Y.; Kennedy, A.W.; Belinson, J.; Xu, Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. N. Y. Acad. Sci 2000, 905, 242–259. [Google Scholar]
- Xu, Y.; Shen, Z.; Wiper, D.W.; Wu, M.; Morton, R.E.; Elson, P.; Kennedy, A.W.; Belinson, J.; Markman, M.; Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280, 719–723. [Google Scholar]
- Tania, M.; Khan, M.A.; Song, Y. Association of lipid metabolism with ovarian cancer. Curr. Oncol 2010, 17, 6–11. [Google Scholar]
- Swinnen, J.V.; Esquenet, M.; Goossens, K.; Heyns, W.; Verhoeven, G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line lncap. Cancer Res 1997, 57, 1086–1090. [Google Scholar]
- Gansler, T.S.; Hardman, W., 3rd; Hunt, D.A.; Schaffel, S.; Hennigar, R.A. Increased expression of fatty acid synthase (oa-519) in ovarian neoplasms predicts shorter survival. Hum. Pathol 1997, 28, 686–692. [Google Scholar]
- Pizer, E.S.; Wood, F.D.; Heine, H.S.; Romantsev, F.E.; Pasternack, G.R.; Kuhajda, F.P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996, 56, 1189–1193. [Google Scholar]
- Scaglia, N.; Chisholm, J.W.; Igal, R.A. Inhibition of stearoylcoa desaturase-1 inactivates acetyl-coa carboxylase and impairs proliferation in cancer cells: Role of ampk. PLoS One 2009, 4. [Google Scholar] [CrossRef]
- Yang, Y.A.; Han, W.F.; Morin, P.J.; Chrest, F.J.; Pizer, E.S. Activation of fatty acid synthesis during neoplastic transformation: Role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res 2002, 279, 80–90. [Google Scholar]
- Chajes, V.; Cambot, M.; Moreau, K.; Lenoir, G.M.; Joulin, V. Acetyl-coa carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006, 66, 5287–5294. [Google Scholar]
- Migita, T.; Narita, T.; Nomura, K.; Miyagi, E.; Inazuka, F.; Matsuura, M.; Ushijima, M.; Mashima, T.; Seimiya, H.; Satoh, Y.; et al. Atp citrate lyase: Activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008, 68, 8547–8554. [Google Scholar]
- Li, J.N.; Mahmoud, M.A.; Han, W.F.; Ripple, M.; Pizer, E.S. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp. Cell Res 2000, 261, 159–165. [Google Scholar]
- Jiang, P.; Du, W.; Wang, X.; Mancuso, A.; Gao, X.; Wu, M.; Yang, X. P53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol 2011, 13, 310–316. [Google Scholar]
- Bensaad, K.; Tsuruta, A.; Selak, M.A.; Vidal, M.N.; Nakano, K.; Bartrons, R.; Gottlieb, E.; Vousden, K.H. Tigar, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126, 107–120. [Google Scholar]
- Hu, W.; Zhang, C.; Wu, R.; Sun, Y.; Levine, A.; Feng, Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA 2010, 107, 7455–7460. [Google Scholar]
- Zhang, F.; Du, G. Dysregulated lipid metabolism in cancer. World J. Biol. Chem 2012, 3, 167–174. [Google Scholar]
- Kushi, L.H.; Mink, P.J.; Folsom, A.R.; Anderson, K.E.; Zheng, W.; Lazovich, D.; Sellers, T.A. Prospective study of diet and ovarian cancer. Am. J. Epidemiol 1999, 149, 21–31. [Google Scholar]
- La Vecchia, C.; Decarli, A.; Negri, E.; Parazzini, F.; Gentile, A.; Cecchetti, G.; Fasoli, M.; Franceschi, S. Dietary factors and the risk of epithelial ovarian cancer. J. Natl. Cancer Inst 1987, 79, 663–669. [Google Scholar]
- Pan, S.Y.; Ugnat, A.M.; Mao, Y.; Wen, S.W.; Johnson, K.C. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol. Biomarkers Prev 2004, 13, 1521–1527. [Google Scholar]
- Risch, H.A.; Jain, M.; Marrett, L.D.; Howe, G.R. Dietary fat intake and risk of epithelial ovarian cancer. J. Natl. Cancer Inst 1994, 86, 1409–1415. [Google Scholar]
- Risch, H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst 1998, 90, 1774–1786. [Google Scholar]
- Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7, 763–777. [Google Scholar]
- Nieman, K.M.; Kenny, H.A.; Penicka, C.V.; Ladanyi, A.; Buell-Gutbrod, R.; Zillhardt, M.R.; Romero, I.L.; Carey, M.S.; Mills, G.B.; Hotamisligil, G.S.; et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med 2011, 17, 1498–1503. [Google Scholar]
- Ueda, S.M.; Yap, K.L.; Davidson, B.; Tian, Y.; Murthy, V.; Wang, T.L.; Visvanathan, K.; Kuhajda, F.P.; Bristow, R.E.; Zhang, H.; et al. Expression of fatty acid synthase depends on nac1 and is associated with recurrent ovarian serous carcinomas. J. Oncol 2010, 2010, 285191. [Google Scholar]
- Swinnen, J.V.; van Veldhoven, P.P.; Timmermans, L.; de Schrijver, E.; Brusselmans, K.; Vanderhoydonc, F.; van de Sande, T.; Heemers, H.; Heyns, W.; Verhoeven, G. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem. Biophys. Res. Commun 2003, 302, 898–903. [Google Scholar]
- Little, J.L.; Wheeler, F.B.; Fels, D.R.; Koumenis, C.; Kridel, S.J. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 2007, 67, 1262–1269. [Google Scholar]
- Zhou, W.; Simpson, P.J.; McFadden, J.M.; Townsend, C.A.; Medghalchi, S.M.; Vadlamudi, A.; Pinn, M.L.; Ronnett, G.V.; Kuhajda, F.P. Fatty acid synthase inhibition triggers apoptosis during s phase in human cancer cells. Cancer Res 2003, 63, 7330–7337. [Google Scholar]
- Zhou, W.; Han, W.F.; Landree, L.E.; Thupari, J.N.; Pinn, M.L.; Bililign, T.; Kim, E.K.; Vadlamudi, A.; Medghalchi, S.M.; El Meskini, R.; et al. Fatty acid synthase inhibition activates amp-activated protein kinase in skov3 human ovarian cancer cells. Cancer Res 2007, 67, 2964–2971. [Google Scholar]
- Rahman, M.T.; Nakayama, K.; Rahman, M.; Katagiri, H.; Katagiri, A.; Ishibashi, T.; Ishikawa, M.; Iida, K.; Nakayama, N.; Otsuki, Y.; et al. Fatty acid synthase expression associated with nac1 is a potential therapeutic target in ovarian clear cell carcinomas. Br. J. Cancer 2012, 107, 300–307. [Google Scholar]
- Tomek, K.; Wagner, R.; Varga, F.; Singer, C.F.; Karlic, H.; Grunt, T.W. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol. Cancer Res 2011, 9, 1767–1779. [Google Scholar]
- Daly, P.F.; Lyon, R.C.; Faustino, P.J.; Cohen, J.S. Phospholipid metabolism in cancer cells monitored by 31p nmr spectroscopy. J. Biol. Chem 1987, 262, 14875–14878. [Google Scholar]
- Anliker, B.; Chun, J. Lysophospholipid g protein-coupled receptors. J. Biol. Chem 2004, 279, 20555–20558. [Google Scholar]
- Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/gpr23 as a novel g protein-coupled receptor for lysophosphatidic acid, structurally distant from the edg family. J. Biol. Chem 2003, 278, 25600–25606. [Google Scholar]
- Lee, C.W.; Rivera, R.; Gardell, S.; Dubin, A.E.; Chun, J. Gpr92 as a new g12/13- and gq-coupled lysophosphatidic acid receptor that increases camp, lpa5. J. Biol. Chem 2006, 281, 23589–23597. [Google Scholar]
- Yanagida, K.; Masago, K.; Nakanishi, H.; Kihara, Y.; Hamano, F.; Tajima, Y.; Taguchi, R.; Shimizu, T.; Ishii, S. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/lpa6. J. Biol. Chem 2009, 284, 17731–17741. [Google Scholar]
- Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; et al. Lpa receptors: Subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol 2010, 50, 157–186. [Google Scholar]
- Mukherjee, A.; Wu, J.; Barbour, S.; Fang, X. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. J. Biol. Chem 2012, 287, 24990–25000. [Google Scholar]
- Yu, S.; Murph, M.M.; Lu, Y.; Liu, S.; Hall, H.S.; Liu, J.; Stephens, C.; Fang, X.; Mills, G.B. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl. Cancer Inst 2008, 100, 1630–1642. [Google Scholar]
- Ren, J.; Xiao, Y.J.; Singh, L.S.; Zhao, X.; Zhao, Z.; Feng, L.; Rose, T.M.; Prestwich, G.D.; Xu, Y. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006, 66, 3006–3014. [Google Scholar]
- Sutphen, R.; Xu, Y.; Wilbanks, G.D.; Fiorica, J.; Grendys, E.C., Jr; LaPolla, J.P.; Arango, H.; Hoffman, M.S.; Martino, M.; Wakeley, K.; et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev 2004, 13, 1185–1191. [Google Scholar]
- Xu, Y.; Gaudette, D.C.; Boynton, J.D.; Frankel, A.; Fang, X.J.; Sharma, A.; Hurteau, J.; Casey, G.; Goodbody, A.; Mellors, A.; et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res 1995, 1, 1223–1232. [Google Scholar]
- Baker, D.L.; Morrison, P.; Miller, B.; Riely, C.A.; Tolley, B.; Westermann, A.M.; Bonfrer, J.M.; Bais, E.; Moolenaar, W.H.; Tigyi, G. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 2002, 287, 3081–3082. [Google Scholar]
- Cai, Q.; Zhao, Z.; Antalis, C.; Yan, L.; Del Priore, G.; Hamed, A.H.; Stehman, F.B.; Schilder, J.M.; Xu, Y. Elevated and secreted phospholipase a(2) activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J 2012, 26, 3306–3320. [Google Scholar]
- Pustilnik, T.B.; Estrella, V.; Wiener, J.R.; Mao, M.; Eder, A.; Watt, M.A.; Bast, R.C., Jr; Mills, GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res 1999, 5, 3704–3710. [Google Scholar]
- Wang, G.L.; Wen, Z.Q.; Xu, W.P.; Wang, Z.Y.; Du, X.L.; Wang, F. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer skov-3 cells. Croat. Med. J 2008, 49, 175–181. [Google Scholar]
- Murthi, P.; Barker, G.; Nowell, C.J.; Rice, G.E.; Baker, M.S.; Kalionis, B.; Quinn, M.A. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol. Oncol 2004, 92, 80–88. [Google Scholar]
- Fishman, D.A.; Liu, Y.; Ellerbroek, S.M.; Stack, M.S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001, 61, 3194–3199. [Google Scholar]
- Jeong, K.J.; Park, S.Y.; Cho, K.H.; Sohn, J.S.; Lee, J.; Kim, Y.K.; Kang, J.; Park, C.G.; Han, J.W.; Lee, H.Y. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012, 31, 4279–4289. [Google Scholar]
- Hu, Y.L.; Tee, M.K.; Goetzl, E.J.; Auersperg, N.; Mills, G.B.; Ferrara, N.; Jaffe, R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst 2001, 93, 762–768. [Google Scholar]
- Ptaszynska, M.M.; Pendrak, M.L.; Bandle, R.W.; Stracke, M.L.; Roberts, D.D. Positive feedback between vascular endothelial growth factor-a and autotaxin in ovarian cancer cells. Mol. Cancer Res 2008, 6, 352–363. [Google Scholar]
- Song, Y.; Wu, J.; Oyesanya, R.A.; Lee, Z.; Mukherjee, A.; Fang, X. Sp-1 and c-myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin. Cancer Res 2009, 15, 492–501. [Google Scholar]
- Imamura, F.; Mukai, M.; Ayaki, M.; Akedo, H. Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn. J. Cancer Res 2000, 91, 811–816. [Google Scholar]
- Sawada, K.; Morishige, K.; Tahara, M.; Ikebuchi, Y.; Kawagishi, R.; Tasaka, K.; Murata, Y. Lysophosphatidic acid induces focal adhesion assembly through rho/rho-associated kinase pathway in human ovarian cancer cells. Gynecol. Oncol 2002, 87, 252–259. [Google Scholar]
- Chang, H.R.; Huang, H.P.; Kao, Y.L.; Chen, S.L.; Wu, S.W.; Hung, T.W.; Lian, J.D.; Wang, C.J. The suppressive effect of rho kinase inhibitor, y-27632, on oncogenic ras/rhoa induced invasion/migration of human bladder cancer tsgh cells. Chem. Biol. Interact 2010, 183, 172–180. [Google Scholar]
- Dong, G.; Loukinova, E.; Chen, Z.; Gangi, L.; Chanturita, T.I.; Liu, E.T.; van Waes, C. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cdna microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the nf-kappab signal pathway. Cancer Res 2001, 61, 4797–4808. [Google Scholar]
- Eck, M.; Schmausser, B.; Scheller, K.; Brandlein, S.; Muller-Hermelink, H.K. Pleiotropic effects of cxc chemokines in gastric carcinoma: Differences in cxcl8 and cxcl1 expression between diffuse and intestinal types of gastric carcinoma. Clin. Exp. Immunol 2003, 134, 508–515. [Google Scholar]
- Shintani, S.; Ishikawa, T.; Nonaka, T.; Li, C.; Nakashiro, K.; Wong, D.T.; Hamakawa, H. Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer. Oncology 2004, 66, 316–322. [Google Scholar]
- Lee, Z.; Swaby, R.F.; Liang, Y.; Yu, S.; Liu, S.; Lu, K.H.; Bast, R.C., Jr; Mills, G.B.; Fang, X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 2006, 66, 2740–2748. [Google Scholar]
- Tokumura, A.; Majima, E.; Kariya, Y.; Tominaga, K.; Kogure, K.; Yasuda, K.; Fukuzawa, K. Identification of human plasma lysophospholipase d, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem 2002, 277, 39436–39442. [Google Scholar]
- Umezu-Goto, M.; Kishi, Y.; Taira, A.; Hama, K.; Dohmae, N.; Takio, K.; Yamori, T.; Mills, G.B.; Inoue, K.; Aoki, J.; et al. Autotaxin has lysophospholipase d activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol 2002, 158, 227–233. [Google Scholar]
- Nam, S.W.; Clair, T.; Kim, Y.S.; McMarlin, A.; Schiffmann, E.; Liotta, L.A.; Stracke, M.L. Autotaxin (npp-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001, 61, 6938–6944. [Google Scholar]
- Nam, S.W.; Clair, T.; Campo, C.K.; Lee, H.Y.; Liotta, L.A.; Stracke, M.L. Autotaxin (atx), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19, 241–247. [Google Scholar]
- Nakamura, K.; Igarashi, K.; Ohkawa, R.; Yokota, H.; Masuda, A.; Nakagawa, S.; Yano, T.; Ikeda, H.; Aoki, J.; Yatomi, Y. Serum autotaxin is not a useful biomarker for ovarian cancer. Lipids 2012, 47, 927–930. [Google Scholar]
- Iwasawa, Y.; Fujii, T.; Nagamatsu, T.; Kawana, K.; Okudaira, S.; Miura, S.; Matsumoto, J.; Tomio, A.; Hyodo, H.; Yamashita, T.; et al. Expression of autotaxin, an ectoenzyme that produces lysophosphatidic acid, in human placenta. Am. J. Reprod. Immunol 2009, 62, 90–95. [Google Scholar]
- Kimura, T.; Itoh, T.; Fusazaki, T.; Matsui, H.; Sugawara, S.; Ogino, Y.; Endo, H.; Kobayashi, K.; Nakamura, M. Low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol ratio predicts lipid-rich coronary plaque in patients with coronary artery disease—integrated-backscatter intravascular ultrasound study. Circ. J 2010, 74, 1392–1398. [Google Scholar]
- Watanabe, N.; Ikeda, H.; Nakamura, K.; Ohkawa, R.; Kume, Y.; Aoki, J.; Hama, K.; Okudaira, S.; Tanaka, M.; Tomiya, T.; et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitisc. J. Clin. Gastroenterol 2007, 41, 616–623. [Google Scholar]
- Aoki, J.; Inoue, A.; Okudaira, S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 2008, 1781, 513–518. [Google Scholar]
- Chae, Y.C.; Kim, J.H.; Kim, K.L.; Kim, H.W.; Lee, H.Y.; Heo, W.D.; Meyer, T.; Suh, P.G.; Ryu, S.H. Phospholipase d activity regulates integrin-mediated cell spreading and migration by inducing gtp-rac translocation to the plasma membrane. Mol. Biol. Cell 2008, 19, 3111–3123. [Google Scholar]
- Eder, A.M.; Sasagawa, T.; Mao, M.; Aoki, J.; Mills, G.B. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: Role of phospholipase d and phospholipase a2. Clin. Cancer Res 2000, 6, 2482–2491. [Google Scholar]
- Ryland, L.K.; Fox, T.E.; Liu, X.; Loughran, T.P.; Kester, M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther 2011, 11, 138–149. [Google Scholar]
- Pewzner-Jung, Y.; Ben-Dor, S.; Futerman, A.H. When do lasses (longevity assurance genes) become cers (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J. Biol. Chem 2006, 281, 25001–25005. [Google Scholar]
- Gatt, S.; Dagan, A. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids. Chem. Phys. Lipids 2012, 165, 462–474. [Google Scholar]
- Radin, N.S. Killing tumours by ceramide-induced apoptosis: A critique of available drugs. Biochem. J 2003, 371, 243–256. [Google Scholar]
- Selzner, M.; Bielawska, A.; Morse, M.A.; Rudiger, H.A.; Sindram, D.; Hannun, Y.A.; Clavien, P.A. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001, 61, 1233–1240. [Google Scholar]
- Von Haefen, C.; Wieder, T.; Gillissen, B.; Starck, L.; Graupner, V.; Dorken, B.; Daniel, P.T. Ceramide induces mitochondrial activation and apoptosis via a bax-dependent pathway in human carcinoma cells. Oncogene 2002, 21, 4009–4019. [Google Scholar]
- Illuzzi, G.; Bernacchioni, C.; Aureli, M.; Prioni, S.; Frera, G.; Donati, C.; Valsecchi, M.; Chigorno, V.; Bruni, P.; Sonnino, S.; et al. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J. Biol. Chem 2010, 285, 18594–18602. [Google Scholar]
- Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S. Targeting sphk1 as a new strategy against cancer. Curr. Drug Targets 2008, 9, 662–673. [Google Scholar]
- Spiegel, S. Sphingosine 1-phosphate: A prototype of a new class of second messengers. J. Leukoc. Biol 1999, 65, 341–344. [Google Scholar]
- Liu, Y.; Chen, Y.; Momin, A.; Shaner, R.; Wang, E.; Bowen, N.J.; Matyunina, L.V.; Walker, L.D.; McDonald, J.F.; Sullards, M.C.; et al. Elevation of sulfatides in ovarian cancer: An integrated transcriptomic and lipidomic analysis including tissue-imaging mass spectrometry. Mol. Cancer 2010, 9. [Google Scholar] [CrossRef]
- Makhlouf, A.M.; Fathalla, M.M.; Zakhary, M.A.; Makarem, M.H. Sulfatides in ovarian tumors: Clinicopathological correlates. Int J. Gynecol. Cancer 2004, 14, 89–93. [Google Scholar]
- ClinicalTrials.gov NCT00986206. Lysophosphatidic acid assay in patients with ovarian cancer or who are at risk for ovarian cancer. Available online: http://clinicaltrials.gov/show/NCT00986206 (accessed on 17 January 2013).
- Shan, L.; Chen, Y.A.; Davis, L.; Han, G.; Zhu, W.; Molina, A.D.; Arango, H.; LaPolla, J.P.; Hoffman, M.S.; Sellers, T.; et al. Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer. PLoS One 2012, 7. [Google Scholar] [CrossRef]
- Munoz-Pinedo, C.; El Mjiyad, N.; Ricci, J.E. Cancer metabolism: Current perspectives and future directions. Cell. Death Dis. 2012, 3. [Google Scholar] [CrossRef]
- Martirosyan, A.; Clendening, J.W.; Goard, C.A.; Penn, L.Z. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer 2010, 10. [Google Scholar] [CrossRef]
- ClinicalTrials.gov NCT00585052. A phase II study of interaction of lovastatin and paclitaxel for patients with refractory or relapsed ovarian cancer. Available online: http://clinicaltrials.gov/show/NCT00585052 (accessed on 16 January 2013).
- Van Vlerken, L.E.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007, 67, 4843–4850. [Google Scholar]
- Swanton, C.; Marani, M.; Pardo, O.; Warne, P.H.; Kelly, G.; Sahai, E.; Elustondo, F.; Chang, J.; Temple, J.; Ahmed, A.A.; et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11, 498–512. [Google Scholar]
- Hanada, K.; Kumagai, K.; Yasuda, S.; Miura, Y.; Kawano, M.; Fukasawa, M.; Nishijima, M. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003, 426, 803–809. [Google Scholar]
- Vidot, S.; Witham, J.; Agarwal, R.; Greenhough, S.; Bamrah, H.S.; Tigyi, G.J.; Kaye, S.B.; Richardson, A. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal 2010, 22, 926–935. [Google Scholar]
Marker | Studies/Methods | References |
---|---|---|
LPA | LPA assays under development in clinical trials. | [82] |
Sulphatides | Elevation of sulphatides in EOC tissue compared to normal tissue by mass spectrometry (LC ESI-MS/MS). | [80] |
PLA2 | Elevated activity of PLA2 in EOC tissue, compared to benign tumours and normal tissue using fluorometric assays. | [44] |
LPLs | Increased levels of LPA, LPI and SIP in plasma from ovarian cancer patients compared to healthy controls using ESI-MS. | [3,41] |
Predictive markers with a significant difference between levels of SIP, LPA and LPC between preoperative and postoperative ovarian cancer patients. | [41] | |
LPLs + CA 125 | Serum measurements of LPLs in conjunction with CA125 greatly improved diagnostic accuracy in early stage serous ovarian cancer and mucinous subtypes using LC ESI-MS/MS. | [83] |
Target | Treatment | Effect | References |
---|---|---|---|
Cholesterol | Statins | Induce apoptosis of ovarian cancer cells. In clinical trials. | [85,86] |
FAS | C93 | Increases cytotoxicity of carboplatin and paclitaxel. Induces cell death in vitro and reduces tumour growth in xenograft mouse model. | [25,29] |
C75 | Reduces cell proliferation in ovarian clear cell carcinoma cell lines. Inhibits growth and survival of ovarian cancer cells in vitro. | [30,31] | |
ATX | ccPA | Increases cytotoxicity of carboplatin. | [90] |
ENPP2 | siRNA | Increases apoptosis of cancer cells with carboplatin. | [90] |
Ceramide | Ceramide | Co-administration with the chemotherapy drugs, paclitaxel or carboplatin, sensitises cancer cells, increasing cell death. | [87] |
CERT | siRNA | Sensitises cancer cells to paclitaxel. | [88] |
© 2013 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Pyragius, C.E.; Fuller, M.; Ricciardelli, C.; Oehler, M.K. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 7742-7756. https://doi.org/10.3390/ijms14047742
Pyragius CE, Fuller M, Ricciardelli C, Oehler MK. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(4):7742-7756. https://doi.org/10.3390/ijms14047742
Chicago/Turabian StylePyragius, Carmen E., Maria Fuller, Carmela Ricciardelli, and Martin K. Oehler. 2013. "Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer" International Journal of Molecular Sciences 14, no. 4: 7742-7756. https://doi.org/10.3390/ijms14047742